10/06/2025 - General information
The Spanish Society of Neurology has awarded the scientific career of the coordinator of the Multiple Sclerosis Unit at Hospital del Mar and the coordinator of the Neuroimmunology Research Group at its research institute. Dr. José Enrique Martínez received the 'Premio SEN Esclerosis Múltiple' on June 4th, during the Institutional Ceremony of the Spanish Society of Neurology, recognizing his scientific work in this field. These awards represent the SEN's recognition of individuals or entities that have contributed to the development of neurology.
Més informació "SEN Multiple Sclerosis Award for Dr. José Enrique Martínez"
25/03/2025 - General information
A new study led by researchers from the Hospital del Mar Research Institute and the Barcelonaβeta Brain Research Center (BBRC), the research centre of the Pasqual Maragall Foundation, has made significant strides in the search for effective blood-based biomarkers for Alzheimer's disease early detection. The research, published in the journal Alzheimer's & Dementia, provides a comprehensive comparison of various plasma biomarkers and their accuracy in detecting Alzheimer's disease in a memory clinic setting.
17/03/2025 - General information
The BAPP, a joint center between the Hospital del Mar Research Institute and Pompeu Fabra University, will maintain this quality seal from the Government of Catalonia until 2028. This recognition highlights its scientific and technical excellence, as well as its capacity for knowledge and technology transfer to the industry. The BioAnalysis, Proteomics and Pharmacology Center (BAPP), part of the Hospital del Mar Research Institute and Pompeu Fabra University, has renewed its TECNIO accreditation, awarded by the Government of Catalonia through ACCIÓ. This accreditation, valid until 2028, identifies and gives visibility to highly capable scientific and technical centers, recognized as developers of cutting-edge technologies and leaders in technology and knowledge transfer to the industry.
Més informació "The Hospital del Mar Research Institute renews the TECNIO accreditation"
07/02/25 - General information
The Hospital del Mar Research Institute and the company Bionure have signed an agreement to establish a strategic collaboration between the two institutions. The objective is the development of new RNA-based therapies for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The research center will be responsible for conducting proof-of-concept studies for potential medications, both in patient cells and in animal models, which is a necessary step before starting clinical trials in humans. RNA therapies for these types of pathologies are a promising tool not only to slow disease progression but also to potentially repair neuronal damage in neurodegenerative diseases with a genetic component.
22/11/2024 - General information
This project will study the short- and long-term impact of steroid sulfation, which is involved in various biological processes, during pregnancy and its influence on maternal mental health and the mother-child bond. The project, "Short- and Long-term Effects of Steroid Sulfation During Pregnancy on Brain Plasticity, Maternal Well-being, and the Mother-Child Bond", led by Dr. Òscar Vilarroya, coordinator of the Neuroimaging of Mental Disorders Research Group at the Hospital del Mar Research Institute, will receive funding from La Marató de TV3 and Catalunya Ràdio. It is one of 26 projects related to sexual and reproductive health selected by the Board of Trustees of La Marató Foundation upon the recommendation of the Advisory Commission. Over 100 proposals were submitted in this edition.
20/11/2024 - General information
The project has received one of the recognitions in the Responsible Research and Innovation in Health awards. The award highlights the added value of the project for incorporating public participation in its design. The PENSA study aims to contribute to the research of effective treatments to prevent or delay dementia.
24/05/2024 - General information
Dr. Marta Torrens, Emeritus Director of Addictions of the Mental Health Institute of the Hospital del Mar and researcher of her research institute, has been selected by the executive committee of the European Union Drugs Agency (EUDA), to be part of its scientific committee. The decision was made on July 4 and Dr. Torrens will be one of the agency's advisors for the next four years. The European Union Agency for Drugs and Drug Addiction is the successor of the former European Monitoring Centre for Drugs and Drug Addiction, with enhanced capabilities and responsibilities.
18/07/2024 - General information
The Hospital del Mar Research Institute will be Olympic again. Three of the professionals of the Institute's Anti-Doping Laboratory of Catalonia will work in the Olympic Laboratory during the Olympic and Paralympic Games in Paris. They are Sergi Coll and Lídia Requena, who will travel to Paris to work at the Laboratory from July 26 to August 11 during the Olympic Games, and Indira Anselmo, who will work from August 28 to September 8, during the Paralympic Games. Sergi Coll is a specialist in the detection of anabolic steroids, and Lídia Requena and Indira Anselmo are specialists in the detection of hormones (erythropoietin, growth hormone...) and blood transfusions.
19/02/2024 - General information
The Ministry of Science, Innovation and Universities and the European Union, through the Next Generation EU program will finance this new phase. It will evaluate the efficacy of CTH120 as an innovative therapy in adult patients with SXF, the most common form of hereditary intellectual disability without specific treatment. The public-private consortium formed by the biotechnology company CONNECTA Therapeutics, the Hospital del Mar Research Institute, the Center for Genomic Regulation (CRG), and the Parc Taulí Research and Innovation Institute (I3PT) will receive 2,7 million euros in funding from the Ministry of Science, Innovation and Universities and the European Union, through the Next Generation EU program, to initiate Phase IIa clinical trials of the drug CTH120 for the treatment of Fragile X syndrome (Fragile X syndrome).
Més informació "Nearly 3 million euros to initiate Phase IIa of CTH120 drug for Fragile X syndrome"
23/03/2023 - General information
The Associació Catalana de Gestors Esportius Professionals has recognized the international projection of the Laboratory. The Associació Catalana de Gestors Esportius Professionals (ACGEP) has awarded the Catalonia Prize for Sports Management on a national or international level to the Catalonian Anti-Doping Laboratory of the Hospital del Mar Medical Research Institute. The award recognizes the role of the Laboratory in projecting Catalonia to the world, its professionalism and its contribution to a cleaner sport. It was also highlighted that it is one of the thirty laboratories accredited in the world by the World Anti-Doping Agency to carry out doping controls on athletes, and that it works for clean sport in various national and international events.
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
